Theravance declares independence from GSK, crafts $250M plan to buy back its own shares
As Theravance Biopharma tries to plot its comeback, it announced Monday morning that it would be buying its own shares from GSK — one of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
